Cardiopulmonary exercise testing (CPET) is a unique diagnostic tool that assesses the functional capacity of the heart, lungs, and peripheral oxidative system in an integrated manner. However, the clinical utility of CPET for evaluating interstitial lung disease (ILD) remains uncertain. The objective of this study was to determine the predictive value of CPET for mortality in subjects with ILD.
METHODS:
We prospectively enrolled subjects with ILD who underwent CPET at a tertiary medical center in Taiwan and followed up their survival status for 12 months. Mortality prediction was based on comparing CPET parameters between subjects who survived and those who died. We further analyzed CPET parameters that showed significant differences using receiver operating characteristic curves to identify their optimal cutoff values.
RESULTS:
A total of 106 newly diagnosed subjects with ILD underwent CPET, and the 1-y mortality rate was 7.5%. Six CPET variables were found to be significant predictors of mortality: peak oxygen consumption, oxygen pulse, end-tidal partial pressure of carbon dioxide, heart rate recovery 1 min after CPET, minute ventilation to carbon dioxide output slope, and functional aerobic impairment. We calculated a summed score by adding the number of CPET variables that exceeded their cutoff values. Subjects with a summed score of 6 had a 1-y survival rate of only 25%, whereas subjects with scores of 0–5 had a survival rate of 98%.
CONCLUSIONS:
In conclusion, the summed score represents a useful tool for screening patients with ILD who can undergo a CPET to determine their prognosis.
LuppiF, SebastianiM, SalvaraniC, BendstrupE, ManfrediA. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol, 2022; 18(2):85-96.
2.
WijsenbeekM, CottinV. Spectrum of fibrotic lung diseases. N Engl J Med, 2020; 383(10):958-968.
3.
TzouvelekisA, KarampitsakosT, KourtidouS, BourosE, TzilasV, KatsarasM, et al. Impact of depression on patients with idiopathic pulmonary fibrosis. Front Med (Lausanne), 2020; 7:29.
4.
Zamora-LegoffJA, KrauseML, CrowsonCS, RyuJH, MattesonEL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology, 2017; 56(3):344-350.
BonellaF, BalaszH, GottsteinE, TheegartenD, CostabelU, TaubeC. The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD).Eur Resp J, 2020; 56:801.
7.
DistlerO, AssassiS, CottinV, CutoloM, DanoffSK, DentonCP, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J, 2020; 55(5):1902026.
8.
JugePA, SolomonJJ, van MoorselCHM, GarofoliR, LeeJS, Louis-SydneyF, et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis–associated interstitial lung disease survival and progression. Semin Arthritis Rheum, 2021; 51(5):996-1004.
9.
HeSH, HeYJ, GuoKJ, LiangX, LiSS, LiTF. Risk factors for progression of interstitial lung disease in Sjögren’s syndrome: a single-centered, retrospective study. Clin Rheumatol, 2022; 41(4):1153-1161.
10.
GonoT, MasuiK, NishinaN, KawaguchiY, KawakamiA, IkedaKet al; the Multicenter Retrospective Cohort of Japanese Patients with Myositis-Associated ILD (JAMI) Investigators. Risk prediction modelling based on a combination of initial serum biomarker levels in polymyositis/dermatomyositis–associated interstitial lung disease. Arthritis Rheumatol, 2021; 73(4):677-686.
11.
AlhamadEH, CalJG. Predictors of mortality in interstitial lung disease patients without pulmonary hypertension. Ann Thorac Med, 2020; 15(4):238-243.
12.
BrownKK, InoueY, FlahertyKR, MartinezFJ, CottinV, BonellaF, et al. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022; 27(4):294-300.
13.
BarrattSL, DavisR, SharpC, PaulingJD. The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review. ERJ Open Res, 2020; 6(3):00027-02020.
14.
GuazziM, ArenaR, HalleM, PiepoliMF, MyersJ, LavieCJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J, 2018; 39(14):1144-1161.
15.
American Thoracic Society, American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med, 2003; 167(2):211-277.
16.
LiguoriG. ACSM’s guidelines for exercise testing and prescription, 11th edition: American College of Sports Medicine; 2022.
17.
GrahamBL, SteenbruggenI, MillerMR, BarjaktarevicIZ, CooperBG, HallGL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med, 2019; 200(8):e70-e88.
18.
GrahamBL, BrusascoV, BurgosF, CooperBG, JensenR, KendrickA, et al. Executive summary: 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J, 2017; 49(1):16E0016.
19.
MezzaniA. Cardiopulmonary exercise testing: basics of methodology and measurements. Ann Am Thorac Soc, 2017; 14(Supplement_1):S3-S11.
20.
VossF, SchuelerM, LauterbachM, BauerA, KatusHA, BeckerR. Safety of symptom-limited exercise testing in a big cohort of a modern ICD population. Clin Res Cardiol, 2016; 105(1):53-58.
21.
Molgat-SeonY, SchaefferMR, RyersonCJ, GuenetteJA. Cardiopulmonary exercise testing in patients with interstitial lung disease. Front Physiol, 2020; 11:832.
22.
StubbeB, IttermannT, GriegerA, WaltherC, GläserS, EwertR. Value of cardiopulmonary exercise testing in prognostic assessment of patients with interstitial lung diseases. J Clin Med, 1609; 11(6).
23.
BruceRA, KusumiF, HosmerD. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J, 1973; 85(4):546-562.
24.
GlaabT, TaubeC. Practical guide to cardiopulmonary exercise testing in adults. Respir Res, 2022; 23(1):9.
25.
SunX, ShiX, CaoY, ZhuH, PudasainiB, YangW, et al. Variation of PETCO2 during incremental exercise and severity of IPAH and CTEPH. BMC Pulm Med, 2022; 22(1):249.
26.
ArmstrongHF, ThirapatarapongW, DussaultNE, BartelsMN. Distinguishing pulmonary hypertension in interstitial lung disease by ventilation and perfusion defects measured by cardiopulmonary exercise testing. Respiration, 2013; 86(5):407-413.
27.
EwertR, IttermannT, HabedankD, HeldM, LangeTJ, HalankM, et al. Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis. BMC Pulm Med, 2019; 19(1):230.
28.
LaytonAM, ArmstrongHF, KimHP, MezaKS, D’OvidioF, ArcasoySM. Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med, 2017; 126:59-67.
29.
VainshelboimB, OliveiraJ, FoxBD, KramerMR. The prognostic role of ventilatory inefficiency and exercise capacity in idiopathic pulmonary fibrosis. Respir Care, 2016; 61(8):1100-1109.
30.
TriantafillidouC, ManaliE, LyberopoulosP, KolilekasL, KagouridisK, GyftopoulosS, et al. The role of cardiopulmonary exercise test in IPF prognosis. Pulm Med, 2013; 2013:514817.
31.
FellCD, LiuLX, MotikaC, KazerooniEA, GrossBH, TravisWD, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2009; 179(5):402-407.
32.
GläserS, ObstA, KochB, HenkelB, GriegerA, FelixSB, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency. PLoS One, 2013; 8(6):e65643.
33.
LimH. The physiology of extracorporeal membrane oxygenation: the Fick principle. Perfusion, 2023; 38(2):236-244.
34.
NicholsS, TaylorC, PageR, Kallvikbacka-BennettA, NationF, GoodmanT, et al. Is cardiorespiratory fitness related to cardiometabolic health and all-cause mortality risk in patients with coronary heart disease? A CARE CR Study. Sports Med Open, 2018; 4(1):22.
35.
LaukkanenJA, AraújoCGS, KurlS, KhanH, JaeSY, GuazziM, KunutsorSK. Relative peak exercise oxygen pulse is related to sudden cardiac death, cardiovascular, and all-cause mortality in middle-age men. Eur J Prev Cardiol, 2018; 25(7):772-782.
36.
BilselT, TerziS, AkbulutT, SayarN, HobikogluG, YesilcimenK. Abnormal heart rate recovery immediately after cardiopulmonary exercise testing in heart failure patients. Int Heart J, 2006; 47(3):431-440.
37.
SipiläK, TikkakoskiA, AlankoS, HaaralaA, HernesniemiJ, LyytikäinenLP, et al. Combination of low blood pressure response, low exercise capacity, and slow heart rate recovery during an exercise test significantly increases mortality risk. Ann Med, 2019; 51(7-8):390-396.
